Developer docs
API playgroundTry for free, no card

Search company profiles

Amplex Diagnostics

Full company profile

uuid003bnzk

Namestring
Amplex Diagnostics
Legal namestring
AmplexDiagnostics GmbH
Websiteurl
eazyplex.com
Company typeenum
Private
Founded yearint
2002
Descriptiontext

AmplexDiagnostics GmbH is a privately held German specialty diagnostics company founded in 2002 and headquartered in Gars-Bahnhof, Germany, with sales and marketing operations in Buseck. The company develops, manufactures, and distributes CE IVD-certified molecular diagnostic kits under the eazyplex® brand, based on isothermal Loop-Mediated Isothermal Amplification (LAMP) combined with real-time fluorescence detection. Its core technical differentiator is the use of lyophilized, ready-to-use reagents that ship and store at room temperature and enable direct testing from patient samples (swabs, blood cultures, urine, CSF, stool, BAL) without DNA/RNA extraction, delivering results in 15–30 minutes. The portfolio spans over 20 CE IVD test kits covering Gram-negative resistance (SuperBug family), MRSA, sepsis (BloodScreen), meningitis (CSF direct), Candida auris, sexually transmitted infections, C. difficile, VRE, EHEC, Pneumocystis jirovecii, and hypervirulent K. pneumoniae, supported by a four-instrument device range (eazyMini, eazyOne, Genie HT, Genie II Mk2).

Amplex generates revenue primarily from sale of CE IVD diagnostic kits and instruments, supplemented by a contract lyophilization service for third-party LAMP assays and authorized resale of OptiGene's Genie instruments in Germany and Austria. The company operates exclusively through a global network of more than 30 regional distributors spanning over 40 countries across Europe, the Middle East, Asia, Africa, Oceania, and Latin America, with no direct end-customer sales channel. Customer segments include hospital microbiology laboratories, university institutes, outpatient health centers (MVZs), infection control departments, and research institutions; named end-user references include Teramo Hospital in Italy. Marketing is driven by peer-reviewed scientific publications (30+ studies), conference participation at events such as ESCMID Global, downloadable technical documentation, and a bilingual German/English website.

The company is founder/management-owned, led by managing directors Dr. Lars Wassill and Dr. Dirk Ganghofner, with no disclosed venture capital, private equity, or parent company ownership. Its quality management system is certified under DIN EN ISO 13485 and the EU IVDR, and all products carry CE IVD certification. Revenue, headcount, and financial performance are not publicly disclosed. The company's strategic positioning emphasizes workflow simplicity, room-temperature logistics, and time-to-result advantages over classical microbiology (24–48 hours) for clinical infectious disease diagnostics.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersGießen-wieseck, Germany
HQ citystring
Gießen-wieseck
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
molecular diagnostics, in vitro diagnostics, infectious disease testing, antimicrobial resistance detection, lyophilized diagnostic reagents
Industry4 codes
PRIMARYHLAAALAC
Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels)
SECONDARYHLAHAOAI
Molecular POCT / NAAT Systems (PCR/Isothermal platforms & cartridges)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics
SECONDARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)
SECONDARYHLAHAAAC
Microbiology & Infectious Disease Diagnostics (Culture/ID/AST)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
NAICS code1 code
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
In Vitro Molecular Diagnostics
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1CE IVD Diagnostic Kits and Reagents
TypeHardware Sales
Description

Amplex Diagnostics generates revenue primarily through the sale of CE IVD-certified molecular diagnostic kits based on the eazyplex® LAMP technology platform. Kits are sold as lyophilized, ready-to-use formats for various pathogen targets including MRSA, carbapenem-resistant bacteria, sepsis pathogens, STDs, and more. Revenue is driven by reagent consumption per test across a global laboratory customer base.

eazyplex.com
2Diagnostic Instruments
TypeHardware Sales
Description

Sale of diagnostic instruments (eazyMini, eazyOne, Genie II, Genie II MK2, Genie HT) that run the eazyplex® test system. The company sells hardware platforms as part of the product ecosystem.

eazyplex.com
3Lyophilization Service for LAMP Assays
TypeProfessional Services
Description

Amplex offers lyophilization services for third-party LAMP assays, converting them into ready-to-use, room-temperature-stable formats compatible with the eazyplex® system. This is a service-based revenue stream.

eazyplex.com
4OptiGene Equipment Resale
TypeHardware Sales
Description

Amplex is an official distributor of OptiGene products (Genie II, Genie III instruments) in Germany and Austria, reselling laboratory equipment as an authorized channel partner.

eazyplex.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 17 records shown
1eazyplex® SuperBug CRE
Description

Molecular rapid test for detection of carbapenemase-producing bacteria including KPC, NDM, OXA-48, OXA-181, VIM, and ESBL genes

eazyplex.com
+16 more records
Core offering1 text field

Amplex Diagnostics develops, manufactures, and distributes CE IVD certified molecular diagnostic kits and instruments under the eazyplex® brand, using isothermal Loop-Mediated Isothermal Amplification (LAMP) combined with real-time fluorescence detection. The lyophilized, ready-to-use reagent kits enable direct testing from patient samples (blood cultures, swabs, CSF, urine, stool) without DNA/RNA extraction, delivering results in 15-30 minutes for pathogen and antibiotic resistance gene detection across gram-negative resistance, MRSA, sepsis, meningitis, STDs, and fungal infections.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Reduced sepsis diagnostic turnaround time from 24/48 hours (classical microbiology) to 1 hour (using eazyplex® BloodScreen algorithm)
+4 more records
Product overview1 text field

Amplex Diagnostics offers the eazyplex® System, a comprehensive CE IVD certified molecular diagnostics platform centered on isothermal LAMP amplification with real-time fluorescence detection. The portfolio comprises four instrument models (eazyMini, eazyOne, Genie HT, Genie II Mk2) and over 20 distinct CE IVD test kit product lines covering major infectious disease categories: Gram-negative resistance (SuperBug CRE, complete, expert, Acineto, AmpC, basic kits), MRSA/MRSAplus, BloodScreen (sepsis panels), Candida auris, STDs, C. difficile, EHEC, Pneumocystis jirovecii, PneumoBug expert, VRE, CSF direct, and hv-K. pneumoniae. All reagents are lyophilized and ready-to-use, shipped and stored at room temperature, with no DNA/RNA extraction required. The company also distributes OptiGene's Genie® II and Genie® III instruments, provides LAMP Designer primer design software, and offers a contract lyophilization service for third-party LAMP assays.

Product and service3 records
1eazyplex® System
CategoryMolecular Diagnostics Platform
Description

A CE IVD certified molecular diagnostics platform combining isothermal LAMP amplification with real-time fluorescence detection. Features lyophilized, ready-to-use reagents shipped and stored at room temperature, with no DNA/RNA extraction required.

2eazyMini
CategoryDiagnostic Instrument
Description

A CE IVD instrument with two independent heating blocks, integrated barcode scanner, intuitive software, and HL7 HIS/LIS connectivity, designed for rapid single tests 24/7 with the best price-performance ratio in the eazyplex® device lineup. Made in Germany.

3eazyOne
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Arrow Diagnostics SRL is Amplex Diagnostics' exclusive distributor for Italy. The partnership was highlighted through a published case study from Teramo Hospital, where the eazyplex® system was established in the clinical pathology lab using Arrow Diagnostics as the equipment provider.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

AxonLab serves as a distributor for Amplex products across multiple European markets including Switzerland, Austria, Poland, Czech Republic, and Slovenia.

3bioactiva diagnostica GmbH (Germany/Egypt/Algeria)
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

bioactiva diagnostica GmbH distributes Amplex products in Germany, Egypt, and Algeria.

eazyplex.com
4OptiGene Ltd (UK)
Strategic tierCoreTypeTechnology or Integration
Description

Amplex Diagnostics is an official distributor of OptiGene products (Genie II and Genie III instruments) for Germany and Austria. The Genie® family of instruments, originally developed by OptiGene, forms the hardware platform for Amplex's LAMP-based eazyplex® diagnostic system. The Genie II, Genie III, and associated consumables are distributed by Amplex under this partnership.

eazyplex.com
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Menarini Diagnósticos S.A. distributes Amplex products in Spain.

6Advanced Technology Company K.S.C. (Kuwait)
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

ATC distributes Amplex products in Kuwait.

eazyplex.com
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

EMM Life Science AB distributes Amplex products in Sweden and Denmark.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Germany-based sample-prep and molecular diagnostics provider with the QIAstat-Dx syndromic platform and broad infectious disease PCR kits covering many of the same resistance and pathogen targets as eazyplex®.

TypeEmerging player
Description

Emerging player in rapid identification and antimicrobial susceptibility testing directly from positive blood cultures, addressing the same sepsis diagnostic use case as Amplex's eazyplex® BloodScreen panels.

3OptiGene
TypeDirect peer
Description

UK-based developer of the Genie® isothermal instruments that form Amplex's core hardware platform; also a strategic technology partner. Both share isothermal amplification roots, and Amplex is OptiGene's official distributor in Germany and Austria.

TypeBroad incumbent
Description

US-based molecular diagnostics leader behind the GeneXpert system, serving the same hospital microbiology customers with rapid PCR panels for MRSA, sepsis, CT/NG, C. difficile and carbapenem resistance that Amplex targets, but with much broader menu and global installed base.

TypeBroad incumbent
Description

US diagnostics and molecular company operating the Panther system for CT/NG, Mycoplasma, HSV and other infectious disease targets overlapping with Amplex's STD and meningitis panels.

6Eiken Chemical
TypeDirect peer
Description

Japanese inventor of Loop-Mediated Isothermal Amplification (LAMP), the underlying chemistry Amplex uses. Eiken licenses its GspSSD polymerase to Amplex and competes directly in LAMP-based IVD reagents for infectious disease and resistance gene detection.

TypeBroad incumbent
Description

French in vitro diagnostics leader offering the BioFire FilmArray syndromic panels plus classical microbiology ID/AST solutions to the same hospital lab customers as Amplex, with deeper commercialization resources.

TypeBroad incumbent
Description

Global IVD giant with the cobas molecular platform and extensive sepsis, MRSA, and CT/NG menus, addressing many of the same indications Amplex serves through its eazyplex® kits but at much larger scale.

TypeDirect peer
Description

US-listed specialty molecular diagnostics company focused on infectious disease testing (C. difficile, CT/NG, group B Strep, HSV, RSV) — a comparable mid-sized specialist serving the same hospital lab customer base as Amplex.

10Abbott Diagnostics
TypeBroad incumbent
Description

Major molecular diagnostics player with the Alinity m and m2000 platforms, offering infectious disease and resistance panels that compete with Amplex's eazyplex® portfolio in hospital microbiology labs.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration3 records

Each record includes

Title, Type, Description, Source

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Amplex Diagnostics

In Vitro Molecular Diagnosticseazyplex.com

What Amplex Diagnostics does

AmplexDiagnostics GmbH is a privately held German specialty diagnostics company founded in 2002 and headquartered in Gars-Bahnhof, Germany, with sales and marketing operations in Buseck. The company develops, manufactures, and distributes CE IVD-certified molecular diagnostic kits under the eazyplex® brand, based on isothermal Loop-Mediated Isothermal Amplification (LAMP) combined with real-time fluorescence detection. Its core technical differentiator is the use of lyophilized, ready-to-use reagents that ship and store at room temperature and enable direct testing from patient samples (swabs, blood cultures, urine, CSF, stool, BAL) without DNA/RNA extraction, delivering results in 15–30 minutes. The portfolio spans over 20 CE IVD test kits covering Gram-negative resistance (SuperBug family), MRSA, sepsis (BloodScreen), meningitis (CSF direct), Candida auris, sexually transmitted infections, C. difficile, VRE, EHEC, Pneumocystis jirovecii, and hypervirulent K. pneumoniae, supported by a four-instrument device range (eazyMini, eazyOne, Genie HT, Genie II Mk2).

Amplex generates revenue primarily from sale of CE IVD diagnostic kits and instruments, supplemented by a contract lyophilization service for third-party LAMP assays and authorized resale of OptiGene's Genie instruments in Germany and Austria. The company operates exclusively through a global network of more than 30 regional distributors spanning over 40 countries across Europe, the Middle East, Asia, Africa, Oceania, and Latin America, with no direct end-customer sales channel. Customer segments include hospital microbiology laboratories, university institutes, outpatient health centers (MVZs), infection control departments, and research institutions; named end-user references include Teramo Hospital in Italy. Marketing is driven by peer-reviewed scientific publications (30+ studies), conference participation at events such as ESCMID Global, downloadable technical documentation, and a bilingual German/English website.

The company is founder/management-owned, led by managing directors Dr. Lars Wassill and Dr. Dirk Ganghofner, with no disclosed venture capital, private equity, or parent company ownership. Its quality management system is certified under DIN EN ISO 13485 and the EU IVDR, and all products carry CE IVD certification. Revenue, headcount, and financial performance are not publicly disclosed. The company's strategic positioning emphasizes workflow simplicity, room-temperature logistics, and time-to-result advantages over classical microbiology (24–48 hours) for clinical infectious disease diagnostics.

Amplex Diagnostics firmographics

Firmographics
Name
Amplex Diagnostics
Legal name
AmplexDiagnostics GmbH
Website
https://eazyplex.com
Company type
Private
Founded year
2002
Operating status
Operating
Headcount range
1–10 employees
Ownership category
akta.pro rank

Amplex Diagnostics industry classification

Industry
Product category
In Vitro Molecular Diagnostics
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAAALAC
Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels)
SECONDARYHLAHAOAI
Molecular POCT / NAAT Systems (PCR/Isothermal platforms & cartridges)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics
SECONDARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)
SECONDARYHLAHAAAC
Microbiology & Infectious Disease Diagnostics (Culture/ID/AST)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics

Keywords

  • Molecular diagnostics
  • In vitro diagnostics
  • Infectious disease testing
  • Antimicrobial resistance detection
  • Lyophilized diagnostic reagents

Where Amplex Diagnostics is headquartered

Location

Headquarters

HQ city
Gießen-wieseck
HQ country
Germany
HQ region
Europe

Offices2 records

Markets served

Amplex Diagnostics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. CE IVD Diagnostic Kits and Reagents: Amplex Diagnostics generates revenue primarily through the sale of CE IVD-certified molecular diagnostic kits based on the eazyplex® LAMP technology platform. Kits are sold as lyophilized, ready-to-use formats for various pathogen targets including MRSA, carbapenem-resistant bacteria, sepsis pathogens, STDs, and more. Revenue is driven by reagent consumption per test across a global laboratory customer base.
  2. Diagnostic Instruments: Sale of diagnostic instruments (eazyMini, eazyOne, Genie II, Genie II MK2, Genie HT) that run the eazyplex® test system. The company sells hardware platforms as part of the product ecosystem.
  3. Lyophilization Service for LAMP Assays: Amplex offers lyophilization services for third-party LAMP assays, converting them into ready-to-use, room-temperature-stable formats compatible with the eazyplex® system. This is a service-based revenue stream.
  4. OptiGene Equipment Resale: Amplex is an official distributor of OptiGene products (Genie II, Genie III instruments) in Germany and Austria, reselling laboratory equipment as an authorized channel partner.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Amplex Diagnostics product offering

Product offering

Core offering

Amplex Diagnostics develops, manufactures, and distributes CE IVD certified molecular diagnostic kits and instruments under the eazyplex® brand, using isothermal Loop-Mediated Isothermal Amplification (LAMP) combined with real-time fluorescence detection. The lyophilized, ready-to-use reagent kits enable direct testing from patient samples (blood cultures, swabs, CSF, urine, stool) without DNA/RNA extraction, delivering results in 15-30 minutes for pathogen and antibiotic resistance gene detection across gram-negative resistance, MRSA, sepsis, meningitis, STDs, and fungal infections.

Product overview

Amplex Diagnostics offers the eazyplex® System, a comprehensive CE IVD certified molecular diagnostics platform centered on isothermal LAMP amplification with real-time fluorescence detection. The portfolio comprises four instrument models (eazyMini, eazyOne, Genie HT, Genie II Mk2) and over 20 distinct CE IVD test kit product lines covering major infectious disease categories: Gram-negative resistance (SuperBug CRE, complete, expert, Acineto, AmpC, basic kits), MRSA/MRSAplus, BloodScreen (sepsis panels), Candida auris, STDs, C. difficile, EHEC, Pneumocystis jirovecii, PneumoBug expert, VRE, CSF direct, and hv-K. pneumoniae. All reagents are lyophilized and ready-to-use, shipped and stored at room temperature, with no DNA/RNA extraction required. The company also distributes OptiGene's Genie® II and Genie® III instruments, provides LAMP Designer primer design software, and offers a contract lyophilization service for third-party LAMP assays.

Differentiator

Problem solved

Functional benefit

Brands

  • eazyplex® SuperBug CRE: Molecular rapid test for detection of carbapenemase-producing bacteria including KPC, NDM, OXA-48, OXA-181, VIM, and ESBL genes
  • eazyplex® SuperBug complete
  • eazyplex® SuperBug expert
  • eazyplex® SuperBug Acineto
  • eazyplex® SuperBug AmpC
  • eazyplex® SuperBug basic
  • eazyplex® MRSA
  • eazyplex® BloodScreen
  • eazyplex® CSF direct
  • eazyplex® C. difficile
  • eazyplex® STD
  • eazyplex® PneumoBug expert
  • eazyplex® VRE
  • eazyplex® EHEC
  • eazyplex® hv-K. pneumoniae
  • eazyplex® Candida auris
  • eazyplex® Pneumocystis jirovecii

Products and services

  • eazyplex® System A CE IVD certified molecular diagnostics platform combining isothermal LAMP amplification with real-time fluorescence detection. Features lyophilized, ready-to-use reagents shipped and stored at room temperature, with no DNA/RNA extraction required.
  • eazyMini A CE IVD instrument with two independent heating blocks, integrated barcode scanner, intuitive software, and HL7 HIS/LIS connectivity, designed for rapid single tests 24/7 with the best price-performance ratio in the eazyplex® device lineup. Made in Germany.
  • eazyOne

Quantifiable outcome

  • Reduced sepsis diagnostic turnaround time from 24/48 hours (classical microbiology) to 1 hour (using eazyplex® BloodScreen algorithm)
  • +4 more outcomes

Companies that use Amplex Diagnostics

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Amplex Diagnostics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability2 records

Feature7 records

Amplex Diagnostics partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core and minor.

  • Arrow Diagnostics SRL (Italy)coreChannel Partner/ Reseller/ DistributorArrow Diagnostics SRL is Amplex Diagnostics' exclusive distributor for Italy. The partnership was highlighted through a published case study from Teramo Hospital, where the eazyplex® system was established in the clinical pathology lab using Arrow Diagnostics as the equipment provider.
  • AxonLab (Switzerland/Austria/Poland/Czech Republic/Slovenia)coreChannel Partner/ Reseller/ DistributorAxonLab serves as a distributor for Amplex products across multiple European markets including Switzerland, Austria, Poland, Czech Republic, and Slovenia.
  • bioactiva diagnostica GmbH (Germany/Egypt/Algeria)coreChannel Partner/ Reseller/ Distributorbioactiva diagnostica GmbH distributes Amplex products in Germany, Egypt, and Algeria.
  • OptiGene Ltd (UK)coreTechnology or IntegrationAmplex Diagnostics is an official distributor of OptiGene products (Genie II and Genie III instruments) for Germany and Austria. The Genie® family of instruments, originally developed by OptiGene, forms the hardware platform for Amplex's LAMP-based eazyplex® diagnostic system. The Genie II, Genie III, and associated consumables are distributed by Amplex under this partnership.
  • Menarini Diagnósticos S.A. (Spain)coreChannel Partner/ Reseller/ DistributorMenarini Diagnósticos S.A. distributes Amplex products in Spain.
  • Advanced Technology Company K.S.C. (Kuwait)minorChannel Partner/ Reseller/ DistributorATC distributes Amplex products in Kuwait.
  • EMM Life Science AB (Sweden/Denmark)minorChannel Partner/ Reseller/ DistributorEMM Life Science AB distributes Amplex products in Sweden and Denmark.

Scale indicators4 records

Recent moves9 records

Expansion highlights5 records

Amplex Diagnostics competitors and assessment

Company assessment

Broad incumbents

  • QIAGEN: Germany-based sample-prep and molecular diagnostics provider with the QIAstat-Dx syndromic platform and broad infectious disease PCR kits covering many of the same resistance and pathogen targets as eazyplex®.
  • Cepheid (Danaher): US-based molecular diagnostics leader behind the GeneXpert system, serving the same hospital microbiology customers with rapid PCR panels for MRSA, sepsis, CT/NG, C. difficile and carbapenem resistance that Amplex targets, but with much broader menu and global installed base.
  • Hologic: US diagnostics and molecular company operating the Panther system for CT/NG, Mycoplasma, HSV and other infectious disease targets overlapping with Amplex's STD and meningitis panels.
  • bioMérieux: French in vitro diagnostics leader offering the BioFire FilmArray syndromic panels plus classical microbiology ID/AST solutions to the same hospital lab customers as Amplex, with deeper commercialization resources.
  • Roche Diagnostics: Global IVD giant with the cobas molecular platform and extensive sepsis, MRSA, and CT/NG menus, addressing many of the same indications Amplex serves through its eazyplex® kits but at much larger scale.
  • Abbott Diagnostics: Major molecular diagnostics player with the Alinity m and m2000 platforms, offering infectious disease and resistance panels that compete with Amplex's eazyplex® portfolio in hospital microbiology labs.

Emerging players

  • Accelerate Diagnostics: Emerging player in rapid identification and antimicrobial susceptibility testing directly from positive blood cultures, addressing the same sepsis diagnostic use case as Amplex's eazyplex® BloodScreen panels.

Direct peers

  • OptiGene: UK-based developer of the Genie® isothermal instruments that form Amplex's core hardware platform; also a strategic technology partner. Both share isothermal amplification roots, and Amplex is OptiGene's official distributor in Germany and Austria.
  • Eiken Chemical: Japanese inventor of Loop-Mediated Isothermal Amplification (LAMP), the underlying chemistry Amplex uses. Eiken licenses its GspSSD polymerase to Amplex and competes directly in LAMP-based IVD reagents for infectious disease and resistance gene detection.
  • Meridian Bioscience: US-listed specialty molecular diagnostics company focused on infectious disease testing (C. difficile, CT/NG, group B Strep, HSV, RSV) — a comparable mid-sized specialist serving the same hospital lab customer base as Amplex.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Amplex Diagnostics social profiles

Digital presence

Amplex Diagnostics compliance and trust

Trust signal

Compliance3 records

Amplex Diagnostics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Amplex Diagnostics leadership team

Management profile

Number of profiles

Profiles2 records

Amplex Diagnostics funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Amplex Diagnostics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Amplex Diagnostics

What does Amplex Diagnostics do?

Amplex Diagnostics develops, manufactures, and distributes CE IVD certified molecular diagnostic kits and instruments under the eazyplex® brand, using isothermal Loop-Mediated Isothermal Amplification (LAMP) combined with real-time fluorescence detection. The lyophilized, ready-to-use reagent kits enable direct testing from patient samples (blood cultures, swabs, CSF, urine, stool) without DNA/RNA extraction, delivering results in 15-30 minutes for pathogen and antibiotic resistance gene detection across gram-negative resistance, MRSA, sepsis, meningitis, STDs, and fungal infections.

Is Amplex Diagnostics a public or private company?

Amplex Diagnostics is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Amplex Diagnostics founded?

Amplex Diagnostics was founded in 2002. It employs 1 to 10 people.

Where is Amplex Diagnostics based?

Amplex Diagnostics is headquartered in Gießen-wieseck, Germany, in the Europe region.

How does Amplex Diagnostics make money?

Four revenue lines are on record. CE IVD Diagnostic Kits and Reagents are the primary driver. The others are diagnostic Instruments, lyophilization Service for LAMP Assays and optiGene Equipment Resale.

Who are Amplex Diagnostics's main competitors?

Broad incumbents on record are QIAGEN, Cepheid (Danaher), Hologic, bioMérieux, Roche Diagnostics and Abbott Diagnostics. Accelerate Diagnostics is listed as an emerging player. Direct peers are OptiGene, Eiken Chemical and Meridian Bioscience.

Does Amplex Diagnostics have an API?

No public API is recorded for Amplex Diagnostics.

What industry is Amplex Diagnostics in?

Amplex Diagnostics's product category is In Vitro Molecular Diagnostics. Its primary akta.pro industry code is HLAAALAC, Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels), with a secondary code of HLAHAOAI, Molecular POCT / NAAT Systems (PCR/Isothermal platforms & cartridges). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business & FinancialNew Innovative Molecular Technology Combination LAMP + CRISPR As CE-IVDAmplexDiagnostics and Scope Biosciences introduced eazySNP, a CE-IVD test combining LAMP and CRISPR to detect genetic variants. The first product, eazySNP C. auris FKS1 S639, detects echinocandin resistance in Candida auris from a yeast colony in 45 minutes. The launch marks Scope Biosciences' entry into human diagnostics.Financial PostNew Innovative Molecular Technology Combination 'LAMP + CRISPR' as CE-IVDAmplexDiagnostics and Scope Biosciences introduced eazySNP, a CE-IVD diagnostic combining LAMP and CRISPR to detect genetic variants. The first test, eazySNP C. auris FKS1 S639, identifies echinocandin resistance mutations in Candidozyma auris from a yeast colony in 45 minutes. The launch marks Scope Biosciences' entry into human diagnostics.PR Newswire APACNew Innovative Molecular Technology Combination "LAMP + CRISPR" as CE-IVDAmplexDiagnostics and Scope Biosciences introduced eazySNP, a CE-IVD diagnostic combining LAMP and CRISPR to detect Candida auris resistance mutations. The test, performed on the eazyMini platform, delivers results in 45 minutes and targets the FKS1 gene. Scope Biosciences marks its entry into human diagnostics.PR Newswire APACNew Innovative Molecular Technology Combination "LAMP + CRISPR" as CE-IVDAmplexDiagnostics and Scope Biosciences launched eazySNP, a LAMP+CRISPR molecular test for Candida auris FKS1 S639 resistance. The first CE-IVD product delivers results in 45 minutes from a yeast colony, marking Scope Biosciences' entry into human diagnostics.AktienNeue innovative molekulare Technologiekombination „LAMP + CRISPR" als CE-IVDAmplexDiagnostics and Scope Biosciences launched eazySNP, a CE-IVD diagnostic combining LAMP and CRISPR to detect C. auris FKS1 mutations linked to echinocandin resistance. The test delivers results in 45 minutes from a yeast colony, marking Scope Biosciences' entry into human diagnostics.NewswireNew Innovative Molecular Technology Combination "LAMP + CRISPR" as CE-IVDAmplexDiagnostics and Scope Biosciences introduced eazySNP, a CE-IVD diagnostic combining LAMP and CRISPR to detect genetic variants. The first test, eazySNP C. auris FKS1 S639, identifies echinocandin resistance in Candidozyma auris from a yeast colony in 45 minutes. The launch marks Scope Biosciences' entry into human diagnostics.PR NewswireNeue innovative molekulare Technologiekombination „LAMP + CRISPR" als CE-IVDAmplexDiagnostics and Scope Biosciences launched eazySNP, a CE-IVD diagnostic combining LAMP and CRISPR to detect C. auris FKS1 mutations linked to echinocandin resistance. The test delivers results in 45 minutes from a yeast colony, marking Scope Biosciences' entry into human diagnostics.PR NewswireNew Innovative Molecular Technology Combination "LAMP + CRISPR" as CE-IVDAmplexDiagnostics and Scope Biosciences introduced eazySNP, a CE-IVD diagnostic combining LAMP and CRISPR to detect genetic variants. The first product, eazySNP C. auris FKS1 S639, identifies echinocandin resistance in Candida auris from a yeast colony in 45 minutes. The launch marks Scope Biosciences' entry into human diagnostics.PR NewswireNew Innovative Molecular Technology Combination "LAMP + CRISPR" as CE-IVDAmplexDiagnostics and Scope Biosciences introduced eazySNP, a CE-IVD diagnostic combining LAMP and CRISPR to detect genetic variants. The first product, eazySNP C. auris FKS1 S639, identifies echinocandin resistance in Candida auris from a yeast colony in 45 minutes. The launch marks Scope Biosciences' entry into human diagnostics.